Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Clinical Trial Facility
mi
from
Morgantown, WV
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Morgantown, WV
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Clinical Trial Facility
mi
from
Milwaukee, WI
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Milwaukee, WI
A Phase 1 Study of MLN9708 in Adult Patients With Advanced Nonhematologic Malignancies
An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Status: Archived
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
A Phase 1 Study of MLN9708 in Adult Patients With Advanced Nonhematologic Malignancies
An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
A Phase 1 Study of MLN9708 in Adult Patients With Advanced Nonhematologic Malignancies
An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Status: Archived
Sarah Cannon Cancer Center
mi
from
Nashville, TN
A Phase 1 Study of MLN9708 in Adult Patients With Advanced Nonhematologic Malignancies
An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Status: Archived
Updated: 1/1/1970
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Alabama Research Center
mi
from
Birmingham, AL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Alabama Research Center
mi
from
Birmingham, AL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Urology Centers of Alabama
mi
from
Homewood, AL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Urology Centers of Alabama
mi
from
Homewood, AL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Alaska Urological Association
mi
from
Anchorage, AK
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Alaska Urological Association
mi
from
Anchorage, AK
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Arizona Urologic Specialists
mi
from
Tuscon, AZ
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Arizona Urologic Specialists
mi
from
Tuscon, AZ
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Orange County Urology
mi
from
Lagua Hills, CA
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Orange County Urology
mi
from
Lagua Hills, CA
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Tri-Valley Urology Medical Group
mi
from
Murrieta, CA
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Tri-Valley Urology Medical Group
mi
from
Murrieta, CA
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Connecticut Clinical Research Center, LLC
mi
from
Middlebury, CT
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Connecticut Clinical Research Center, LLC
mi
from
Middlebury, CT
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
South Florida Medical Research
mi
from
Miami, FL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
South Florida Medical Research
mi
from
Miami, FL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
DCT -Celebration, LLC dba Discovery Clinical Trials
mi
from
Celebration, FL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
DCT -Celebration, LLC dba Discovery Clinical Trials
mi
from
Celebration, FL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Pinellas Urology Inc.
mi
from
St. Petersburg, FL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Pinellas Urology Inc.
mi
from
St. Petersburg, FL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Palm Beach Urology Associates
mi
from
Wellington, FL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Palm Beach Urology Associates
mi
from
Wellington, FL
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Summit Research Institute
mi
from
Bloomington, IN
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Summit Research Institute
mi
from
Bloomington, IN
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Northeast Indiana Research
mi
from
Fort Wayne, IN
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Northeast Indiana Research
mi
from
Fort Wayne, IN
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Urology Center Research Institute
mi
from
Englewood, NJ
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Urology Center Research Institute
mi
from
Englewood, NJ
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Urology Group of New Mexico
mi
from
Albuquerque, NM
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Urology Group of New Mexico
mi
from
Albuquerque, NM
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Premier Medical Group of Hudson
mi
from
Columbia, NY
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Premier Medical Group of Hudson
mi
from
Columbia, NY
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
University Urology Associates
mi
from
, NY
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
University Urology Associates
mi
from
, NY
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Urology Associates
mi
from
Nashville, TN
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Urology Associates
mi
from
Nashville, TN
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Urology of Virginia
mi
from
Norfolk, VA
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Status: Archived
Updated: 1/1/1970
Urology of Virginia
mi
from
Norfolk, VA
ARRY-334543 With Docetaxel in Advanced Solid Tumors
A Phase 1b Study to Assess the Safety and Pharmacokinetics of ARRY-334543 With Docetaxel in Patients With Advanced Solid Tumors
Status: Archived
University of Colorado at Denver and Health Sciences Center
mi
from
Denver, CO
ARRY-334543 With Docetaxel in Advanced Solid Tumors
A Phase 1b Study to Assess the Safety and Pharmacokinetics of ARRY-334543 With Docetaxel in Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
University of Colorado at Denver and Health Sciences Center
mi
from
Denver, CO
ARRY-334543 With Docetaxel in Advanced Solid Tumors
A Phase 1b Study to Assess the Safety and Pharmacokinetics of ARRY-334543 With Docetaxel in Patients With Advanced Solid Tumors
Status: Archived
Mayo Cancer Center
mi
from
Rochester, MN
ARRY-334543 With Docetaxel in Advanced Solid Tumors
A Phase 1b Study to Assess the Safety and Pharmacokinetics of ARRY-334543 With Docetaxel in Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Mayo Cancer Center
mi
from
Rochester, MN
ARRY-334543 With Docetaxel in Advanced Solid Tumors
A Phase 1b Study to Assess the Safety and Pharmacokinetics of ARRY-334543 With Docetaxel in Patients With Advanced Solid Tumors
Status: Archived
Sarah Cannon Cancer Center
mi
from
Nashville, TN
ARRY-334543 With Docetaxel in Advanced Solid Tumors
A Phase 1b Study to Assess the Safety and Pharmacokinetics of ARRY-334543 With Docetaxel in Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors
Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Given Intravenously to Patients With Advanced Solid Tumors
Status: Archived
TGen Clinical Research Service
mi
from
Scottsdale, AZ
Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors
Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Given Intravenously to Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
TGen Clinical Research Service
mi
from
Scottsdale, AZ
Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors
Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Given Intravenously to Patients With Advanced Solid Tumors
Status: Archived
San Diego Oncology and Hematology Associates, Inc.
mi
from
Encinitas, CA
Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors
Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Given Intravenously to Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
San Diego Oncology and Hematology Associates, Inc.
mi
from
Encinitas, CA
Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors
Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Given Intravenously to Patients With Advanced Solid Tumors
Status: Archived
Premier Oncology Group
mi
from
Scottsdale, AZ
Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors
Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Given Intravenously to Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Premier Oncology Group
mi
from
Scottsdale, AZ
Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors
Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Given Intravenously to Patients With Advanced Solid Tumors
Status: Archived
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors
Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Given Intravenously to Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Correlation Between Skin Carotenoid Levels and Previous History of Skin Cancer
Comparison of Skin Carotenoid Levels Between Subjects With History of Cutaneous Squamous Cell Carcinoma and Subjects With History of Basal Cell Carcinoma Versus a Control Group
Status: Archived
Clinical Unit for Research Trials in Skin
mi
from
Boston, MA
Correlation Between Skin Carotenoid Levels and Previous History of Skin Cancer
Comparison of Skin Carotenoid Levels Between Subjects With History of Cutaneous Squamous Cell Carcinoma and Subjects With History of Basal Cell Carcinoma Versus a Control Group
Status: Archived
Updated: 1/1/1970
Clinical Unit for Research Trials in Skin
mi
from
Boston, MA
Pharmacodynamic Study of Axitinib in Patients With Solid Tumors
Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies
Status: Archived
University of Wisconsin-Madison, Department of Dermatology
mi
from
Madison, WI
Pharmacodynamic Study of Axitinib in Patients With Solid Tumors
Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies
Status: Archived
Updated: 1/1/1970
University of Wisconsin-Madison, Department of Dermatology
mi
from
Madison, WI
Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk
Total Xonoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Risk
Status: Archived
University of Wisconsin-Madison
mi
from
Madison, WI
Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk
Total Xonoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Risk
Status: Archived
Updated: 1/1/1970
University of Wisconsin-Madison
mi
from
Madison, WI
A Study of 7 Day's of Erlotinib Before Surgery, Followed by After Surgery Erlotinib-gemcitabine in Patients With Pancreatic Cancer
UAB 0808, A Phase II Study of Short-course Preoperative Erlotinib Followed by Post-operative Erlotinib-gemcitabine in Patients With Resectable Pancreatic Adenocarcinoma
Status: Archived
University of Alabama - Burmingham
mi
from
Birmingham, AL
A Study of 7 Day's of Erlotinib Before Surgery, Followed by After Surgery Erlotinib-gemcitabine in Patients With Pancreatic Cancer
UAB 0808, A Phase II Study of Short-course Preoperative Erlotinib Followed by Post-operative Erlotinib-gemcitabine in Patients With Resectable Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
University of Alabama - Burmingham
mi
from
Birmingham, AL
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
Phase II Trial of Sorafenib Combined With Doxorubicin Eluting Bead-Transarterial Chemoembolization (LC Bead-TACE) for Patients With Hepatocellular Carcinoma
Status: Archived
Johns Hopkins Hosp
mi
from
Baltimore, MD
Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
Phase II Trial of Sorafenib Combined With Doxorubicin Eluting Bead-Transarterial Chemoembolization (LC Bead-TACE) for Patients With Hepatocellular Carcinoma
Status: Archived
Updated: 1/1/1970
Johns Hopkins Hosp
mi
from
Baltimore, MD
Efficacy and Safety and Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
Phase II and Pharmacokinetic Study of Avastin and Doxil in the Treatment of Platinum-resistant or Refractory Ovarian Cancer
Status: Archived
Univ. of New Mexico cancer research and treatment center
mi
from
Albuquerque, NM
Efficacy and Safety and Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
Phase II and Pharmacokinetic Study of Avastin and Doxil in the Treatment of Platinum-resistant or Refractory Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Univ. of New Mexico cancer research and treatment center
mi
from
Albuquerque, NM
Efficacy and Safety and Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
Phase II and Pharmacokinetic Study of Avastin and Doxil in the Treatment of Platinum-resistant or Refractory Ovarian Cancer
Status: Archived
New York University Langone Medical Center
mi
from
New York, NY
Efficacy and Safety and Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
Phase II and Pharmacokinetic Study of Avastin and Doxil in the Treatment of Platinum-resistant or Refractory Ovarian Cancer
Status: Archived
Updated: 1/1/1970
New York University Langone Medical Center
mi
from
New York, NY
Efficacy and Safety and Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
Phase II and Pharmacokinetic Study of Avastin and Doxil in the Treatment of Platinum-resistant or Refractory Ovarian Cancer
Status: Archived
Bellevue Hospital Center
mi
from
New York, NY
Efficacy and Safety and Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
Phase II and Pharmacokinetic Study of Avastin and Doxil in the Treatment of Platinum-resistant or Refractory Ovarian Cancer
Status: Archived
Updated: 1/1/1970
Bellevue Hospital Center
mi
from
New York, NY
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)
Status: Archived
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)
Status: Archived
Updated: 1/1/1970
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)
Status: Archived
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)
Status: Archived
Updated: 1/1/1970
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)
Status: Archived
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)
Status: Archived
Updated: 1/1/1970
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)
Status: Archived
University of California Davis Cancer Center
mi
from
Sacramento, CA
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)
Status: Archived
Updated: 1/1/1970
University of California Davis Cancer Center
mi
from
Sacramento, CA
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)
Status: Archived
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)
Status: Archived
Updated: 1/1/1970
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)
Status: Archived
Howard University Hospital
mi
from
Washington,
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)
Status: Archived
Updated: 1/1/1970
Howard University Hospital
mi
from
Washington,
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)
Status: Archived
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)
Status: Archived
Updated: 1/1/1970
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)
Status: Archived
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)
Status: Archived
Updated: 1/1/1970
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)
Status: Archived
Minnesota Oncology Hematology-Edina
mi
from
Edina, MN
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)
Status: Archived
Updated: 1/1/1970
Minnesota Oncology Hematology-Edina
mi
from
Edina, MN